Brief: Capricor Says Co,Nippon Enter Partnership For Commercialization,Distribution Of Cap-1002 In U.S.
25/01/2022 10:05
Jan 25 (Reuters) - Capricor Therapeutics Inc CAPR.O :
* CAPRICOR THERAPEUTICS AND NIPPON SHINYAKU ENTER
PARTNERSHIP FOR
EXCLUSIVE COMMERCIALIZATION AND DISTRIBUTION OF CAP-1002 FOR THE
TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY IN THE U.S.
* CAPRICOR THERAPEUTICS - TO RECEIVE AN UPFRONT PAYMENT OF
$30
MILLION, ADDITIONAL POTENTIAL MILESTONE PAYMENTS OF UP TO $705
MILLION
* CAPRICOR THERAPEUTICS - PIVOTAL PHASE 3, HOPE-3 TRIAL
CLEARED BY
FDA TO PROCEED, INITIATION OF TRIAL UNDERWAY
* CO TO RECEIVE MEANINGFUL DOUBLE-DIGIT PERCENTAGE OF
REVENUE
BASED ON PRODUCT SALES
Source text for Eikon: ID:nGNX1vSzKn
Further company coverage: CAPR.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nippon Shinyaku
See all newsTable: Nippon Shinyaku -Q1 group results (IFRS)
Brief: Elixirgen Therapeutics And Nippon Shinyaku Enter Into An Option Agreement For The Development And Commercialization Of Exg-7001 For Duchenne Muscular Dystrophy
Table: Nippon Shinyaku -2025/26 group results (IFRS)
Table: Nippon Shinyaku -2025/26 parent results
Table: Nippon Shinyaku -9-MTH group results (IFRS)